

CDER Office of Compliance Drug Shortage Overview

*Silvia Wanis, PharmD., MS, BCPPS, CPH, RAC
CDR, U.S. Public Health Service
Senior Regulatory Officer
Incidents, Recalls, and Shortages Branch
Division of Supply Chain Integrity
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research*

OBJECTIVES

- Discuss CDER Office of Compliance's Mission, Organizational Structure, and Role.
- Define CDER's Multidisciplinary Drug Shortage Mitigation Process.
- Describe Interagency Coordination Efforts between Office of Compliance and the Drug Shortage Staff.
- Provide Key Recommendations.

Who We Are




CDER Office of Compliance Mission:

To shield the public from poor quality, unsafe, and ineffective drugs through proactive compliance strategies and risk-based enforcement actions.

Incidents, Recalls, and Shortages Branch Role:

Evaluation and classification of drug recalls; FDA's point of contact for and support to the Drug Shortage Staff by coordinating all CDER Office of Compliance program actions for management of a drug shortage.


Drug Shortage Mitigation: A Multidisciplinary Approach



Drug Shortage Mitigation

- Incoming shortage proposals from Industry:
Incidents, Recalls and Shortages Branch (IRSB) consolidates CDER Office of Compliance (OC) recommendations and provides OC's position to a firm's shortage proposal to the Drug Shortage Staff (DSS).
- Outgoing shortage evaluations from Office of Compliance to Drug Shortage Staff:
IRSB communicates CDER OC considerations to DSS prior to issuance of a Warning Letter or taking any enforcement action.
- Proactive Recall notifications to the Drug Shortage Staff

Drug Shortage Mitigation: A Multidisciplinary Approach



Key Recommendations



Promote Voluntary Compliance

Adhere to the Food, Drug, and Cosmetics Act



Ensure Adequate Investigation

Thoroughly analyze root cause of shortage



Provide a Realistic Timeline

Outline a timeline for investigating product defects and scheduling restarts after shutdowns



Anticipate Potential Issues and Maintain Frequent Communication

*Identify risks that could lead to shortages early
Ensure up-to-date knowledge of CMO processes and facilities*

Key Recommendations



Consult with FDA Field Offices

Reach out for guidance on potential recalls



Build Robust Inventories

Prior to major manufacturing changes (e.g., facility upgrades or ownership transfers)



Provide Short-Long-Term Proposals

Address potential shortage issues in notifications to the FDA



Engage in Dialogue with FDA

Collaborate on long-term solutions and remediation efforts



U.S. FOOD & DRUG
ADMINISTRATION